Home Zinc Finger Nucleases
Zinc Finger Nucleases
- 10x Genomics
- A-Lists
- AgBio
- Age-Related Disorders
- Aging
- AGTC
- alcohol
- Alexandria Real Estate Equities
- Allergic Diseases
- Application Notes
- Artificial Intelligence
- Autoimmune Disorders
- Bacterial Diseases
- Bacteriophage
- Base Editing
- Bayer
- BeiGene
- Biodefense/Bioterrorism
- Bioethics
- Biomarker Discovery
- BioNTech
- BioPerspectives
- Blockchain
- Blood Disorders
- Boehringer Ingelheim
- Bone disorders
- Brexit
- Bristol-Myers Squibb
- canine
- Cardiovascular Disease
- Careers
- Celgene
- Cell Analysis
- Cell Biology
- Cell Culture
- Cell Line Development
- Cell Signaling
- Cell Therapy
- Cellular Analysis
- China
- Chromatography
- Circadian Rhythm
- Commentary
- Compound Synthesis
- Computational Biology
- Computer Simulation
- COVID-19 Candidates
- CRISPR
- CRISPR/Cas9
- Danaher
- Developmental Disorders
- DNA Repair
- Drug Resistance
- Ear Disorders
- Economic development
- Education and training
- eGenesis
- Electrophoresis
- Eli Lilly
- Employment Trends
- Endocrine Disorders
- Evolution
- Extracellular Matrix
- Eye Disorders
- Fill and Finish
- Financing
- Five Prime Therapeutics
- Flow Cytometry
- Forensics
- Fungal Diseases
- Gastrointestinal Disorders
- GEN 40
- GEN Edge
- Genentech
- Genetic Disease Testing
- Genetics
- Glycan Analysis
- Glycoproteins
- GWAS
- Hematologic Conditions
- Histology
- HPLC
- Hypertension
- Imaging
- Immunoassay
- Immunochemistry
- Immunology
- In-vitro Fertilization
- Industry News
- Inflammatory Diseases
- Information Management
- Insights
- interleukin
- Ion Channels
- Ireland
- Kidney Diseases
- Kinases
- Literature Review
![Sangamo Therapeutics aims to position itself as a leader in the development of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) cell therapies for immunological diseases with its planned acquisition of TxCell. [Source: TxCell]](https://www.genengnews.com/wp-content/uploads/2018/08/ENTrIA_recognition_EN_without_entria1024x9291472362223-324x160.png "Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition")
